Why Are Barclays Analysts Bullish on Eli Lilly and Bristol-Myers Squibb

Related Articles

Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now

8 months ago

Why Are Institutional Investors Still Bullish on Eli Lilly

7 months ago

Why Are UnitedHealth Group and Bristol-Myers Squibb Attracting Hedge Funds

5 months ago

Is Bristol Myers Squibb's New Multiple Myeloma Drug a Game Changer

8 months ago

Category

You may also like

Stock News•2 weeks ago

Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

Bristol Myers Squibb pairs a high dividend yield with net income recovery from oncology and cardiovascular, while Eli Lilly posts rapid revenue and profit growth on obesity and diabetes leadership.

BMY

Share

Stock News•1 months ago

Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder

Bristol Myers Squibb shares have risen over 17% year-to-date, with speculation that AstraZeneca could acquire the company driving the bull case.

BMY

Share

Stock News•1 months ago

Wall Street Bulls Look Optimistic About Lilly (LLY): Should You Buy?

Eli Lilly (LLY) holds bullish Wall Street analyst ratings, with media reports on rating changes potentially influencing its stock price. Investors weigh sell-side recommendations when deciding on LLY ...

LLY

Share